Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Chinese Patent Office
QuintilesIMS
Baxter
Argus Health
Julphar

Generated: September 16, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ABALOPARATIDE

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Clinical Trials for Abaloparatide

Trial ID Title Status Sponsor Phase Summary
NCT01343004 Study to Evaluate the Safety and Efficacy of BA058 (Abaloparatide) for Prevention of Fracture in Postmenopausal Women Completed Radius Health, Inc. Phase 3 The purpose of this study is to determine whether BA058 (abaloparatide), a parathyroid hormone-related peptide, is effective in preventing fractures in postmenopausal women with severe osteoporosis who are at risk of fractures.
NCT01657162 Twenty Four Month Extension Study of BA058-05-003 Active, not recruiting Radius Health, Inc. Phase 3 The purpose of this study is to provide 24 months of standard of care data on subjects previously enrolled in study BA058-05-003.
NCT01674621 Phase 2 Study of BA058 (Abaloparatide) Transdermal Delivery in Postmenopausal Women With Osteoporosis Completed Nordic Bioscience A/S Phase 2 To determine the clinical safety and efficacy of BA058 Transdermal in otherwise healthy postmenopausal women with osteoporosis as assessed by changes in bone mineral density (BMD) and serum markers of bone metabolism when compared to Transdermal Placebo and BA058 Injection for 6 months of treatment.
NCT01674621 Phase 2 Study of BA058 (Abaloparatide) Transdermal Delivery in Postmenopausal Women With Osteoporosis Completed Radius Health, Inc. Phase 2 To determine the clinical safety and efficacy of BA058 Transdermal in otherwise healthy postmenopausal women with osteoporosis as assessed by changes in bone mineral density (BMD) and serum markers of bone metabolism when compared to Transdermal Placebo and BA058 Injection for 6 months of treatment.
NCT03512262 Safety and Efficacy of Abaloparatide-SC in Men With Osteoporosis (ATOM) Recruiting Radius Health, Inc. Phase 3 A 12 month study to measure the efficacy and safety of abaloparatide in men with osteoporosis.
NCT03623633 Comparative Antiresorptive Efficacy Discontinuation of Denosumab Not yet recruiting Massachusetts General Hospital Phase 4 Osteoporosis remains a significant healthcare burden for the United States. Current FDA-approved osteoporosis treatments include teriparatide, abaloparatide, bisphosphonates, denosumab, and raloxifene. Denosumab is a fully human monoclonal antibody that specifically binds to receptor activator of nuclear factor kappa-B ligand (RANKL). Denosumab potently suppresses osteoclastic activity but bone turnover rapidly normalizes and bone turnover marker levels can rebound above baseline levels after the drug is discontinued. The proposed study will help us determine the relative efficacy of two oral antiresorptive medications that are FDA-approved for treatment of postmenopausal osteoporosis (alendronate and raloxifene) in preventing the rebound increase in bone turnover that occurs after denosumab discontinuation.
NCT03708926 Effect of Abaloparatide on Lumbar Disc Degeneration Not yet recruiting Johns Hopkins University Phase 2 Low back pain is a major public health issue as the leading cause of disability globally. Degeneration of intervertebral disc (IVD) disorder is once source of low back pain. Current treatment options for low back pain secondary to degeneration of intervertebral disc include conservative care, steroid injections, prescription pain medications, physical therapy, or surgery, such as discectomy or laminectomy. Treatments focus on addressing manifested symptoms rather than functional causes, and symptomatic treatment of discogenic low back pain is less than ideal. The investigators have recently found that parathyroid hormone (PTH) effectively attenuates disc degeneration in aged mice. This clinical trial will test if 3-months of daily PTH-related protein (PTHrP), abaloparatide will improve pain, function, and disc health in people with low back pain secondary to lumbar disc degeneration.
>Trial ID >Title >Status >Phase >Summary

Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Abaloparatide

Condition Name

Condition Name for Abaloparatide
Intervention Trials
Osteoporosis 4
Postmenopausal Osteoporosis 2
Osteoporosis of Vertebrae 2
Osteoporosis Localized to Spine 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Abaloparatide
Intervention Trials
Osteoporosis 6
Osteoporosis, Postmenopausal 5
Osteoporotic Fractures 1
Syndrome 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Abaloparatide

Trials by Country

Trials by Country for Abaloparatide
Location Trials
United States 14
Estonia 3
Poland 3
Denmark 3
Brazil 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Abaloparatide
Location Trials
Maryland 4
Georgia 3
Colorado 3
Massachusetts 2
Florida 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Abaloparatide

Clinical Trial Phase

Clinical Trial Phase for Abaloparatide
Clinical Trial Phase Trials
Phase 4 1
Phase 3 4
Phase 2 3
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Abaloparatide
Clinical Trial Phase Trials
Not yet recruiting 4
Recruiting 2
Completed 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Abaloparatide

Sponsor Name

Sponsor Name for Abaloparatide
Sponsor Trials
Radius Health, Inc. 5
Johns Hopkins University 1
Massachusetts General Hospital 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Abaloparatide
Sponsor Trials
Industry 6
Other 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Teva
McKinsey
Accenture
Medtronic
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.